These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26375012)

  • 1. Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.
    Ferguson MJ; Rhodes SD; Jiang L; Li X; Yuan J; Yang X; Zhang S; Vakili ST; Territo P; Hutchins G; Yang FC; Ingram DA; Clapp DW; Chen S
    Pediatr Blood Cancer; 2016 Feb; 63(2):206-13. PubMed ID: 26375012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of
    Burks CA; Rhodes SD; Bessler WK; Chen S; Smith A; Gehlhausen JR; Hawley ET; Jiang L; Li X; Yuan J; Lu Q; Jacobsen M; Sandusky GE; Jones DR; Clapp DW; Blakeley JO
    Mol Cancer Ther; 2019 Dec; 18(12):2321-2330. PubMed ID: 31527226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
    Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
    Wu J; Dombi E; Jousma E; Scott Dunn R; Lindquist D; Schnell BM; Kim MO; Kim A; Widemann BC; Cripe TP; Ratner N
    Pediatr Blood Cancer; 2012 Feb; 58(2):173-80. PubMed ID: 21319287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
    Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
    BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
    Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
    Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.
    Staser K; Yang FC; Clapp DW
    Curr Opin Hematol; 2010 Jul; 17(4):287-93. PubMed ID: 20571392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
    Wang ZH; Li Q; Ruan SQ; Xiao Q; Liu Y; Hu YT; Hu LF; Chen HY; Zheng S; Zhang SZ; Ding KF
    J Zhejiang Univ Sci B; 2014 Aug; 15(8):701-12. PubMed ID: 25091988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
    Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
    PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
    Staser K; Yang FC; Clapp DW
    Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
    Yang FC; Chen S; Clegg T; Li X; Morgan T; Estwick SA; Yuan J; Khalaf W; Burgin S; Travers J; Parada LF; Ingram DA; Clapp DW
    Hum Mol Genet; 2006 Aug; 15(16):2421-37. PubMed ID: 16835260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.
    Demestre M; Herzberg J; Holtkamp N; Hagel C; Reuss D; Friedrich RE; Kluwe L; Von Deimling A; Mautner VF; Kurtz A
    J Neurooncol; 2010 May; 98(1):11-9. PubMed ID: 19921098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
    Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
    Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.
    Kavian N; Servettaz A; Marut W; Nicco C; Chéreau C; Weill B; Batteux F
    Arthritis Rheum; 2012 Jun; 64(6):1990-2000. PubMed ID: 22213155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.
    Mautner VF; Hartmann M; Kluwe L; Friedrich RE; Fünsterer C
    Neuroradiology; 2006 Mar; 48(3):160-5. PubMed ID: 16432718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
    Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
    Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 19. Size of tooth crowns and position of teeth concerning the extension of facial plexiform neurofibroma in patients with neurofibromatosis type 1.
    Friedrich RE; Giese M; Stelljes C; Froeder C; Scheuer HA
    Anticancer Res; 2012 May; 32(5):2207-14. PubMed ID: 22593511
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.